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(Sybert, 2010). We postulate that the
phenotypic difference between these
nevi may be related to the extent of the
mutation, as well as body site–specific
embryological patterns and environment.
The knowledge of the genetic basis of
nevus sebaceus and its associated syn-
drome represents a further step toward
understanding genotype–phenotype cor-
relations arising from genetic mosaicism.
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TO THE EDITOR
Epidermal genetic mosaicism is evident
as stripes of affected skin that typically
appear in S- or V-shaped whorled,
streaked, and linear patterns called lines
of Blaschko (Blaschko, 1901). These
patterns represent dorsoventral migratory
pathways of neuroectoderm during em-
bryogenesis (Moss et al., 1993). Mosaic
lesions result from somatic mutation
during development, with timing of
such events determining the extent and
distribution of skin involvement. Epidermal
nevi (EN) are common cutaneous
mosaic disorders seen in 0.1–0.3% of
births, and fall into two classes: kera-
tinocytic epidermal nevi (KEN) and
organoid epidermal nevi, which includes
nevus sebaceus (NS) and follicular
nevi (Solomon and Esterly, 1975). NS
comprises approximately half of EN,
and typically appears on the scalp as a
yellowish–orange linear plaque with
hyperkeratosis, acanthosis, a markedly
increased number of sebaceous lobules,
and abortive hair follicles with resulting
alopecia (Figure 1a–d). In contrast to
KEN, in which neoplasia is rare, tumors
develop in nearly 14% of all NS cases,
and in more than 23% of affected
adults (Cribier et al., 2000), suggest-
ing that the mutation(s) causing NS
also increase the risk of tumorigenesis
(Figure 1e–g).
Recently, somatic mosaicism has
been identified in KEN using SNaPshot
assays to identify mutations in mitogen-
activated protein kinase (MAPK) pathway
genes including FGFR3, HRAS, KRAS,
NRAS, and PIK3CA. Activating Ras
mutations, including HRAS p.Gly13Arg
and KRAS p.Gly12Asp, were most com-
mon and accounted for 39% of KEN,
with HRAS mutations predominating
(Hafner et al., 2012). Similar appro-
aches have been used in NS, identi-
fying HRAS p.Gly13Arg in 91% of
lesions and KRAS p.Gly12Asp in 5%
of lesions (Groesser et al., 2012). We
present an independent, complemen-
tary approach to genetic pathogenesis
in NS, in which we used whole-exome
sequencing to characterize the spectrum
of de novo coding mutations present
within NS lesions.
See related commentary on pg 597
Abbreviations: EN, epidermal nevi; KEN, keratinocytic epidermal nevi; LOH, loss of heterozygosity; MAPK,
mitogen-activated protein kinase; NS, nevus sebaceus
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For our study cohort, we identified
five individuals with NS and performed
exome sequencing of paired DNA
from blood and NS tissue in each
(Supplementary Table S1 online). Gene-
tic variants were annotated and com-
pared to identify de novo somatic
mutations present solely within NS tis-
sue and not in germ-line DNA. By using
this analysis, we identified two genes
with recurrent somatic mutations: three
NS samples had an identical somatic
mutation in HRAS (p.Gly13Arg), and the
remaining two had a somatic mutation at
the Gly12 residue of KRAS (p.Gly12Asp
and p.Gly12Val, respectively) (Figure 2,
Supplementary Figure S1 online). Further-
more, no genes other than HRAS and
KRAS were found to be mutated in more
than one lesion. Notably, one sample
showed a concurrent HRAS p.Gly13Arg
and a BRAF p.Arg347Gln mutation,
which has not been previously described
as a germ-line or somatic mutation.
This BRAF mutation was the only other
somatic mutation found in exome
sequences of these five NS samples.
NS105 NS111
NS107 NS107
NS
SCP
NS117 NS117 NS124
Figure 1. Clinical and microscopic features of nevus sebaceus. (a, b) Solitary, well-demarcated lesions on the scalp of two individuals show alopecia and a
yellow–orange waxy appearance. (c) On histological examination, there is epidermal acanthosis, papillomatosis, and hyperkeratosis with a marked increase in the
number of sebaceous lobules and abortive hair follicles, scale bar¼ 288mm, which is more evident at (d) higher magnification, scale bar¼ 85mm. (e–g) Up to 20%
of nevus sebaceus (NS) lesions develop tumors, including syringocystadenomas, trichoblastomas, trichilemmomas, and tubular apocrine adenomas. (e) Nevus
sebaceus with syringocystadenoma papilliferum (SCP) composed of villous structures lined by a columnar epithelium with stromal plasma cells, scale
bar¼ 570mm, which is most evident at (f) higher magnification, scale bar¼92mm. (g) A trichoblastoma arising within a nevus sebaceus shows a well-
circumscribed nodule of basaloid cells with a dense fibrocytic stroma, scale bar¼ 92mm.
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To examine whether these mutations
were present uniquely in the epidermis,
and not in the underlying dermis, we
used laser capture microdissection to
prepare DNA independently from the
epidermis and dermis of NS lesions and
then performed Sanger sequencing with
HRAS- or KRAS-specific primers. We
found the mutant allele in an approxi-
mately equimolar ratio in the epidermis
and sebaceous lobules, but it was en-
tirely absent in the dermis and blood
(Supplementary Figures S2 and S3
online). Employing Sanger sequencing,
we evaluated 11 additional paired sam-
ples for HRAS and KRAS mutations, and
all were found to have the same somatic
p.Gly13Arg HRAS mutation (Supple-
mentary Table S2 online; Supplemen-
tary Figure S3 online).
Prior studies have reported that up to
40% of NS lesions exhibit loss of hetero-
zygosity (LOH) on chromosome 9q,
inclusive of PTCH (Xin et al., 1999).
Examination of exome data from our
discovery cohort found no evidence of
LOH in NS lesions at this locus or else-
where (Supplementary Figure S4 online).
Recognizing that HRAS and KRAS are
oncogenes, that observed mutations
could serve as an initiating event in mul-
tistep carcinogenesis (Knudson, 2001),
and that tumors frequently develop in
NS, we sought to determine whether
tumors arise specifically in HRAS or KRAS
mutation-positive lesions. Neoplasms
arising within NS are typically benign
and consist primarily of trichoblastomas,
syringocystadenoma papilliferum, trichi-
lemmomas, and tubular apocrine ade-
nomas (Cribier et al., 2000), although
occasional basal cell carcinomas and
rarely more aggressive malignant tumors
have been reported (Moody et al.,
2012). We identified 11 archival NS
specimens containing tumors, isolated
DNA from the NS portion of the lesion,
and found that all samples had an HRAS
p.Gly13Arg mutation (Supplementary
Table S2 online, Supplementary
Figure S5 online). The spectrum of
additional genetic events necessary for
tumorigenesis in NS lesions remains
unknown.
In total, 27 NS samples were evalu-
ated, with 25 harboring an identical
HRAS mutation (p.Gly13Arg), and two
exhibiting a KRAS mutation in the adja-
cent paralogous residue (p.Gly12Asp or
p.Gly12Val). The occurrence of multi-
ple, tightly clustered somatic mutations
in adjacent residues of these highly
homologous proteins is definitive proof
of a role for these mutations in NS and
suggests a gain-of-function mechanism.
Indeed, expression of the KRAS
p.Gly12Asp allele within murine hair
follicles reproduces features of NS in-
cluding abortive hair follicles and epi-
dermal and sebaceous gland hyperplasia
(Lapouge et al., 2011; Mukhopadhyay
et al., 2011).
Missense mutations at codons 12 and
13 of HRAS and KRAS, respectively, are
common in malignancies, including
squamous cell carcinoma, and lead to
constitutive activation of Ras by block-
ing the activity of GTPase-activating
proteins (Grewal et al., 2011). Ras
isoforms are central regulators of the
MAPK pathway, which controls cell
proliferation, differentiation, and sur-
vival. Rare inherited disorders caused
by germ-line mutations in Ras and
other MAPK pathway members, known
as ‘‘RASopathies,’’ include Costello,
Noonan, and cardio-facio-cutaneous
syndrome. These show variable cutane-
ous features, particularly hyperkeratosis,
palmoplantar keratoderma, papillomas,
and hair abnormalities in addition to
craniofacial and systemic findings. KEN
and NS have not been reported in
affected individuals. Notably, HRAS
p.Gly13Arg and KRAS p.Gly12Asp
have not been reported as germ-line
mutations in these or other disorders,
and KRAS p.Gly12Asp leads to
embryonic lethality in mice, suggesting
that both mutations grossly disrupt
embryonic development and are thus
likely to be found primarily in mosaic
states (Tuveson et al., 2004). Our
findings confirm the predominance of
HRAS mutations in NS, including those
with tumors (Groesser et al., 2012), and
provide evidence that HRAS and KRAS
mutations are sufficient to cause NS
without genome instability, LOH, or
secondary mutation.
The marked sebaceous hyperplasia
observed in NS, which are found almost
exclusively on the scalp and face, is not
seen in KEN, which appear primarily on
the torso, despite identical underlying
somatic HRAS and KRAS mutations. This
suggests that body site determines phe-
notype and is supported by a report of a
contiguous linear nevoid lesion extending
from the scalp to the neck with tran-
sition in clinical and histologic appear-
ance from KEN on the upper back and
neck to NS on the scalp (Waltz et al.,
1999). The specific determinants of
such site-specific phenotypes are
unknown, although distinct epithelial–
mesenchymal interactions are a possible
cause.
Sample Position (hg18) Gene
Base
change
Protein
effect
No. of reads
for tissue
Ref.
No. of reads
for blood
Ref. P -value
NS101
NS102
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NS107
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Chr11:524,286
Chr11:524,286
Chr11:524,286
Chr12:25,289,551
Chr12:25,289,551
HRAS
HRAS
HRAS
KRAS
KRAS
G>C
G>C
G>C
G>T
G>A
G13R
G13R
G13R
G12V
G12D
96
212
135
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154
17
62
19
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31
70
123
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102
77
1
0
0
0
0
1.2×10–3
8.9×10–12
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1.6×10–10
9.1×10–6
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KRAS
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Figure 2. Exome sequencing reveals somatic HRAS and KRAS mutations in nevus sebaceus tissue.
(a) HRAS and KRAS mutation annotation, including genomic position, nucleotide change, protein
consequence, and number of reference and nonreference reads obtained from paired sequencing of tissue
and blood in five independent, unrelated nevus sebaceus cases. Significance of the mutant allele frequency
difference between tissue and blood DNA was calculated with a one-tailed Fisher’s exact test. When
corrected for multiple testing, 2.4106 is the threshold for genome-wide significance. In each case,
HRAS and KRAS mutations showed the lowest P-value. (b) Alignment of the N-termini of HRAS and KRAS
reveals identical residues through position 94, with an overall 95% identity and 99% similarity. The first 50
amino acids are shown for the wild-type and each mutant protein, with mutant residues indicated in red.
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Human subjects gave written,
informed consent to the study protocol,
which was approved by the Yale
Human Investigational Committee, and
complies with the Declaration of
Helsinki Principles.
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TO THE EDITOR
The new RAF inhibitor vemurafenib
represents one of the first specifi-
cally targeted drugs for melanoma
(Bollag et al., 2010; Flaherty et al.,
2010; Joseph et al., 2010). However,
some individuals receiving vemurafenib
develop eruptive squamous neo-
plasms such as keratoacanthomas (KAs)
(Chapman et al., 2011). KAs are
usually considered low-grade squa-
mous proliferations (Cribier et al.,
1999; Clausen et al., 2006), and are
often interpreted as a subtype of
squamous cell carcinoma (SCC). Their
clinical course involves rapid growth
followed by spontaneous involution.
The mechanism by which KAs
develop is still unknown. Improved
understanding of the molecular and
genetic basis of KA formation would
allow their improved management.
To investigate genes involved in the
development of KAs in patients receiv-
ing vemurafenib, we obtained biopsy
specimens and studied gene expression
profiles by a microarray approach; full
details are available in the Supplemen-
tary Material online. These biopsies
were originally obtained by theAbbreviations: KA, keratoacanthoma; MAP, mitogen-activated protein; SCC, squamous cell carcinoma
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